Home › Funds › RA CAPITAL MANAGEMENT, L.P. › NAMS

RA CAPITAL MANAGEMENT, L.P. position in NAMS

NEWAMSTERDAM PHARMA COMPANY · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 9,550,191 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q2 2026 13F filing — a position valued at US$323.7M, representing 2.81% of its reported portfolio and ranking #8 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed NAMS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)9.55M sh
Reported value held$323.66M
Portfolio Weight2.81%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s NAMS position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in NAMS in Q3 2023 at 9,000,000 shares (US$83.2M). The position peaked in Q4 2025 at 9,550,191 shares, worth US$335.0M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 9,550,191 shares valued at US$323.7M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 9.00M $83.25M New
Q4 2023 7.86M $87.84M Reduce
Q1 2024 7.86M $185.98M Hold
Q2 2024 8.06M $154.91M Add
Q3 2024 8.06M $133.86M Hold
Q4 2024 8.85M $227.32M Add
Q1 2025 10.14M $207.54M Add
Q2 2025 10.14M $183.62M Hold
Q3 2025 10.14M $288.35M Hold
Q4 2025 9.55M $335.02M Reduce
Q1 2026 9.55M $305.70M Hold
Q2 2026 9.55M $323.66M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NAMS and 13F data

NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 43 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), FCPM III SERVICES B.V. (US$287.7M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NAMS

All NAMS fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held NAMS?

RA CAPITAL MANAGEMENT, L.P. has disclosed NAMS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in NAMS?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 9.55M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $323.66M, representing 2.81% of its reported portfolio and ranking #8.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling NAMS?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in NAMS. The position peaked in Q4 2025 at 9.55M shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., FCPM III SERVICES B.V., DEERFIELD MANAGEMENT COMPANY, L.P., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.